Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).

NCT06401538 is registered in ClinicalTrials.gov with Bright Minds Biosciences Pty Ltd as lead sponsor.

NCT NCT06401538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06401538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).
Lead sponsor
Bright Minds Biosciences Pty Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
December 5, 2024
Completion date
November 30, 2025
Enrollment
20 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

absence epilepsy, dravet syndrome, jeavons syndrome, lennox gastaut syndrome